Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 564 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR Nivolumab Plus Ipilimumab Demonstrates Long-Term Survival Benefit in Patients with Advanced... May 28, 2024 FDA Approves Nivolumab for Resected Oesophageal or Gastro-oesophageal Junction Cancer May 25, 2021 From Awareness to Action: Putting Cancer Disparities in the Rearview Mirror March 21, 2024 Reunión anual de la ASCO 2021: Inmunoterapia para el melanoma y el... May 19, 2021 Load more HOT NEWS 177Lu-PSMA-617 Prolongs rPFS Relative to Androgen Receptor Pathway Inhibitor Change, with... Fragment Analysis Is a More Reliable MET Exon 14 Screening Strategy... A Penny for Your Thoughts Wishes for a New Year!
